智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上药东英(江苏)药业有限公司(以下简称“上药东英”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于注射用硫酸艾沙康唑(以下简称“该药品”)的《药品注册证书》(证书编号：2026S03379)，该药品获得批准生产。注射用硫酸艾沙康唑适用于治疗成人和1岁及以上儿童患者下列感染：侵袭性曲霉病、侵袭性毛霉病。
智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上药东英(江苏)药业有限公司(以下简称“上药东英”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于注射用硫酸艾沙康唑(以下简称“该药品”)的《药品注册证书》(证书编号：2026S03379)，该药品获得批准生产。注射用硫酸艾沙康唑适用于治疗成人和1岁及以上儿童患者下列感染：侵袭性曲霉病、侵袭性毛霉病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.